Evidence map›Paper›PMID 34988221›Full record

ArticleInternational journal of genomics2021

Identification of Circulating Exosomal miR-101 and miR-125b Panel Act as a Potential Biomarker for Hepatocellular Carcinoma.

Li Sun, Mu Xu, Guoying Zhang, Lin Dong, Jie Wu, Chenchen Wei, Kexin Xu, Lu Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of genomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Diagnostic value of exosomes in patients with liver cancer: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Li SunLaboratory Medicine Center, the Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.ORCID https://orcid.org/0000-0001-9991-7158
Mu XuDepartment of Clinical Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Guoying ZhangDepartment of Clinical Laboratory, Nanjing Integrated Traditional Chinese and Western Medicine Hospital, Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu, China.ORCID https://orcid.org/0000-0001-7841-6450
Lin DongDepartment of Clinical Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Jie WuDepartment of Clinical Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Chenchen WeiCancer Medical Center, the Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Kexin XuLaboratory Medicine Center, the Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Lu ZhangLaboratory Medicine Center, the Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Second Affiliated Hospital of Nanjing Medical University · CNNanjing Medical University · CNNanjing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is one of the most common cancers worldwide with high mortality, and there is an urgent need of new diagnosis measures. This study is aimed at investigating whether circulating exosomal miRNAs could act as biomarkers for the diagnosis of HCC.

methodsA four-stage strategy was adopted in this study. Candidate miRNA was selected by comprehensive analysis of four GEO datasets and TCGA database. The expression of candidate miRNAs in serum exosomal samples were examined through qRT-PCR. The diagnostic utility of the final validated miRNAs was examined by receiver operating characteristic (ROC) curve analysis.

resultsAfter synthetical analysis of four GEO datasets, six miRNAs were selected as candidates due to their higher differential fold change. miR-101 and miR-125b were selected as candidate miRNAs to further investigate their potential as biomarkers for HCC due to their differential fold change and their influence on overall survival based on the TCGA database. As a result, miR-101 and miR-125b expressions were remarkably downregulated in both tissues and serum exosomes of patients with HCC. The area under the ROC curves (AUCs) of circulating exosomal miR-101 and miR-125b were 0.894 (95% CI, 0.793-0.994) and 0.812 (95% CI, 0.675-0.950), respectively. The combination of the two miRNAs presented higher diagnostic utility for HCC (AUC = 0.953).

conclusionThe exosomal miR-101 and miR-125b panel in the serum may act as a noninvasive biomarker for HCC detection.

Identifiers

PMID34988221
PMCPMC8723878
OpenAlexW4200515458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.